Author:
Abbasi Ahmed,Peeke Stephen,Shah Nishi,Mustafa Jennat,Khatun Fariha,Lombardo Amanda,Abreu Michelly,Elkind Richard,Fehn Karen,de Castro Alyssa,Wang Yanhua,Derman Olga,Nelson Randin,Uehlinger Joan,Gritsman Kira,Sica R. Alejandro,Kornblum Noah,Mantzaris Ioannis,Shastri Aditi,Janakiram Murali,Goldfinger Mendel,Verma Amit,Braunschweig Ira,Bachier-Rodriguez Lizamarie
Abstract
AbstractAxicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Cited by
119 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献